WCLC 2023: Perioperative Durvalumab Does Not Negatively Impact Surgery in Non-Small Cell Lung Cancer
Neoadjuvant durvalumab plus chemotherapy showed a tolerable surgical safety profile and higher complete resection rates
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.